RxDoctor Payments Data

Terry Belden, MD

Family Medicine · Longs, SCNPI 1467428821

Payments from drug & device makers

$6,231in general payments, 2019–2025

Across 361 payments — averaging $17.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$892
  • Amgen$541
  • AbbVie$485
  • AstraZeneca$381
  • Novartis$376
  • Kowa Pharmaceuticals America, Inc.$313
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$6,231100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,231 in reported general payments places this provider in the 85th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$200,770
Medicare patients
480
Services billed
2,470

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban140$109,533
JanuviaSitagliptin Phosphate54$67,432
OzempicSemaglutide41$61,477
FarxigaDapagliflozin Propanediol52$50,584
MounjaroTirzepatide38$42,721
XareltoRivaroxaban29$21,905
Repatha SureclickEvolocumab12$17,715
LinzessLinaclotide28$15,719
TrintellixVortioxetine Hydrobromide17$13,193
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$11,812
JanumetSitagliptin Phos/Metformin Hcl18$11,752
MyrbetriqMirabegron18$11,260
Breo ElliptaFluticasone/Vilanterol16$11,135
EntrestoSacubitril/Valsartan12$8,285
Spiriva HandihalerTiotropium Bromide12$6,320

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$239$109,533140 claims
MerckJanuvia, Janumet$166$79,18472 claims
Novo NordiskOzempic$892$61,47741 claims
AstraZenecaFarxiga$381$50,58452 claims
Lilly USA, LLCMounjaro$130$42,72138 claims
GSKTrelegy Ellipta, Breo Ellipta$193$22,94831 claims
Johnson & JohnsonXarelto$308$21,90529 claims
AbbVieLinzess, Synthroid$485$19,11981 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$233$13,19317 claims
Astellas Pharma US IncMyrbetriq$213$11,26018 claims
NovartisEntresto$376$8,28512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Longs

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →